The anticipated arrival of generic semaglutide, the active ingredient in popular weight loss and diabetes drugs like Ozempic and Wegovy, remains years away, with the earliest possible FDA approval not expected until at least 2032. This timeline is due to existing patent protections held by the drug’s manufacturers, despite a recent legal victory for Viatris in a patent litigation dispute that could potentially expedite the process.
Currently, no FDA-approved generic version of semaglutide is available in the United States. The delay is causing significant financial strain for patients who rely on the medication for managing type 2 diabetes or obesity. While semaglutide has proven to be a breakthrough treatment, the high cost—often near $1,000 per month without insurance—limits access for many.
The lack of a generic alternative has led some patients to explore compounded versions of semaglutide, which are custom-formulated medications created by pharmacies. However, the FDA does not approve these compounded drugs, raising concerns about their safety and efficacy. Health care providers advise patients to discuss the risks and benefits of compounded semaglutide before considering it as an option.
The situation is further complicated by the fact that semaglutide is marketed under different brand names—Ozempic and Rybelsus for diabetes and Wegovy for weight loss—all containing the same active ingredient. In other words that even if a generic version of semaglutide becomes available, it may not immediately address the cost concerns for all patients, as coverage for weight loss medications often differs from that for diabetes treatment.
Recent policy changes, including federal drug price negotiations, are expected to lower the cost of Ozempic for some Americans, but the extent of these savings remains to be seen. The Noom healthcare company is also offering access to prescription weight loss medication, but the availability and affordability of these options vary.
The delay in generic competition is not unique to semaglutide. Complex patent protections and manufacturing challenges often hinder the development of generic versions of newer drugs. However, the growing pressure to lower prescription drug costs, coupled with legal challenges to existing patents, may ultimately accelerate the availability of more affordable alternatives.
